EDUFLUVAC

Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure

Coordinatore	EUROPEAN VACCINE INITIATIVE - EEIG    more  Organization address address: IM NEUERHEIMER FELD 307 city: Heidelberg postcode: 69120 contact info Titolo: Dr. Nome: Odile Cognome: Leroy Email: send email Telefono: +49 6221565890 Fax: +49 6221565727
Nazionalità Coordinatore	Germany [DE]
Totale costo	6˙088˙877 €
EC contributo	4˙647˙149 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-11-01   -   2017-10-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	EUROPEAN VACCINE INITIATIVE - EEIG  Organization address address: IM NEUERHEIMER FELD 307 city: Heidelberg postcode: 69120 contact info Titolo: Dr. Nome: Odile Cognome: Leroy Email: send email Telefono: +49 6221565890 Fax: +49 6221565727	DE (Heidelberg)	coordinator	930˙000.00
2	INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA  Organization address address: Av. da Republica, Quinta do Marques S/N city: OEIRAS postcode: 2781901 contact info Titolo: Dr. Nome: Elsa Cognome: Vieira Email: send email Telefono: 351214000000 Fax: 351214000000	PT (OEIRAS)	participant	1˙263˙336.00
3	STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER  Organization address address: LANGE KLEIWEG 161 city: RIJSWIJK ZH postcode: 2288 GJ contact info Titolo: Mr. Nome: Willem Cognome: Slingerland Email: send email Telefono: +31 152842543 Fax: +31 152842600	NL (RIJSWIJK ZH)	participant	983˙670.00
4	REDBIOTEC AG  Organization address address: WAGISTRASSE 23 city: SCHLIEREN postcode: 8952 contact info Titolo: Mr. Nome: Christian Cognome: Schaub Email: send email Telefono: +41 44 738 20 00 Fax: +41 44 738 20 01	CH (SCHLIEREN)	participant	716˙780.00
5	STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK  Organization address address: Costerweg 50 city: WAGENINGEN postcode: 6701BH contact info Titolo: Dr. Nome: Norbert Cognome: Stockhofe Email: send email Telefono: 31320238382	NL (WAGENINGEN)	participant	374˙250.00
6	ETNA BIOTECH SRL  Organization address address: STRADA VINCENZO LANCIA 57 city: CATANIA postcode: 95100 contact info Titolo: Mr. Nome: Antonio Cognome: Di Mauro Email: send email Telefono: +39 0952500276 Fax: +39 0952500276	IT (CATANIA)	participant	240˙000.00
7	Department of Health  Organization address address: Quarry House, Quarry Hill city: Leeds postcode: LS2 7UE contact info Titolo: Mrs. Nome: Amanda Cognome: King Email: send email Telefono: +44 1707 641352	UK (Leeds)	participant	139˙113.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'As current influenza vaccines only afford limited protection against seasonal as well as pandemic influenza, and require regular updating, the development of a “universal” influenza vaccine that can provide broad coverage against different strains within a subtype or even across subtypes has become a key health care priority in both industrialized and low and middle income countries. EDUFLUVAC aims to develop an influenza vaccine that educates the immune system to recognise common influenza epitopes, using a combination of influenza haemagglutinin (HA) antigens delivered on a single virus-like particle. This vaccine concept, using the proven, modern technology of baculovirus VLPs will enable enhanced cross linking of B-cell receptors and favour induction of B-cell responses against common epitopes essential for long-lasting cross recognition and protection. The mechanism underlying the broadening of antibody responses is the increased relative concentration of common epitopes diluting out strain specific epitopes. This will be achieved by testing the ability of a combination of historic HA variants to protect against a variety of modern isolates. A similar approach for developing a novel vaccine for pandemic use will be tested. The knowledge generated will provide Proof of Principle in relevant animal models for an influenza vaccine that does not have to be updated annually, does not have to be manufactured on an annual basis and will not require an annual vaccination campaign. It will also provide for an economically viable large scale production platform for influenza vaccine which, in the event of a pandemic, can manufacture rapidly high quantities of vaccine. All industrial partners (including two SMEs) will benefit from the compilation of the regulatory dossier for transfer to larger vaccine companies and the deeper knowledge integration emanating from EDUFLUVAC in a $2.8 billion global annual influenza vaccine market.'